Akashi Therapeutics is a clinical-stage biopharmaceutical company developing treatments for Duchenne muscular dystrophy (DMD) and other rare pediatric diseases. Its lead candidate, HT-100 (delayed-release halofuginone), is an orally available small molecule designed to reduce fibrosis and inflammation and promote healthy muscle fiber regeneration in DMD patients. HT-100 has been granted orphan designation in the U.S. and E.U. and fast track designation in the U.S., and is being evaluated in a phase 1b/2a multi-center clinical program to assess safety, tolerability, exploratory biomarkers, and efficacy endpoints. Akashi was founded by two patient organizations, Charley’s Fund and the Nash Avery Foundation, and is managed by drug development veterans. The company follows a cooperative funding model backed largely by patient advocacy organizations and has raised a cumulative total of more than $2.5 million from 25 patient groups, including a recent collective $1.5 million round. Akashi says it continues to treat patients in the ongoing trial and anticipates reporting additional progress in the months to come.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2014